APAlexander N. Prossnitz

Alexander N. Prossnitz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexander N. Prossnitz has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Small-Angle Neutron Scattering Reveals Structural Hierarchy of Polymer– Nanoparticle Hydrogels

    by Noah Eckman, Olivia M. Saouaf, Carolyn K. Jons, Sai Venkatesh Pingali, Alexander N. Prossnitz, Catherine M. Kasse, Danielle J. Mai, Eric A. Appel


  • Evolving Transport Properties of Dynamic Hydrogels Enable Self‐Tuning of Short‐ and Long‐Term Cargo Delivery

    by Samya Sen, Changxin Dong, Carolyn K. Jons, Wencke Reineking, Alakesh Alakesh, Noah Eckman, Ye Eun Song, Alexander N. Prossnitz, Eric A. Appel

    Hydrogels are crosslinked polymer networks with high water content, widely employed in biomedical applications such as drug delivery, tissue engineering, and regenerative medicine. Injectable, depot‐forming hydrogels enable sustained release of therapeutic agents by modulating macromolecular diffusion through dynamic polymer networks. However, achieving reliable control over release kinetics remains a challenge, as the injection process induces shear‐mediated disruption of transient crosslinks, leading to an initial burst release that can cause local toxicity and compromise therapeutic efficacy. Here, we present a hydrogel formulation strategy designed to restore network structure post‐injection through rapid reformation of dynamic crosslinks, enabling time‐dependent regulation of diffusion properties. By tuning viscoelastic parameters, including stress relaxation time and network recovery rate, we reduced the extent of burst release without compromising sustained delivery. Using model protein cargo, we demonstrate under both in vitro and in vivo settings that hydrogels with faster crosslink reformation kinetics exhibit significantly lower early‐phase release while maintaining long‐term delivery comparable to unmodified formulations. These results establish a mechanistic framework for decoupling short‐ and long‐term release behavior, offering a universally applicable strategy for precise drug delivery in soft tissue environments.


  • Open Access

    Enabling global access to potent subunit vaccines with a simple and scalable injectable hydrogel platform

    by Priya Ganesh, Alexander N. Prossnitz, Carolyn K. Jons, Noah Eckman, Alakesh Alakesh, Ye Eun Song, Samya Sen, Eric A. Appel

    We have developed a simple, scalable, and globally accessible injectable hydrogel platform to improve responses to subunit vaccines against current and emerging pandemic threats.

  • Ultrahigh-concentration biologic therapeutics enabled by spray drying with a glassy surfactant excipient

    by Carolyn K. Jons, Alexander N. Prossnitz, Noah Eckman, Changxin Dong, Ashley Utz, Eric A. Appel

    Biopharmaceuticals such as peptides and antibodies have become critical to health care. Despite their exceptional potency and specificity, biopharmaceuticals are prone to aggregation, which can limit efficacy. These therapies therefore often require low-concentration formulations as well as cold storage to maintain stability; however, high doses are required to treat many diseases. Most approved protein drug products are administered intravenously, imposing excessive burdens on patients. New approaches are needed to formulate proteins at high concentrations to enable less burdensome subcutaneous injection, preferably with an autoinjector that can be used directly by patients. To address this challenge, we report a subcutaneously injectable protein delivery platform composed of spray-dried protein microparticles suspended in a nonsolvent liquid carrier. These microparticles contain only biopharmaceuticals and a high–glass transition temperature polyacrylamide-derived copolymer excipient that affords key benefits over traditional excipients. First, the excipient improved stabilization of biopharmaceuticals through the spray-drying process, and second, it improved morphology and properties of the spray-dried particles, enhancing suspension injectability. We demonstrated with albumin, human immunoglobulin G, and an anti-COVID monoclonal antibody (IDBiologics) that this technology enables ultrahigh-concentration protein formulations (exceeding 500 milligrams per milliliter) that are injectable through standard needles with clinically relevant injection forces. In addition, experiments with two clinically relevant antibody drugs show that these ultrahigh-concentration formulations reduce required injection volumes without altering pharmacokinetics or efficacy in mice. This approach could nearly triple the number of commercial protein drugs amenable to subcutaneous administration, improving access to these critical biopharmaceuticals.


  • Open Access

    Polyacrylamide-Based Antimicrobial Copolymers to Replace or Rescue Antibiotics

    by Shoshana C. Williams, Madeline B. Chosy, Carolyn K. Jons, Changxin Dong, Alexander N. Prossnitz, Xinyu Liu, Hector Lopez Hernandez, Lynette Cegelski, Eric A. Appel

    Antibiotics save countless lives each year and have dramatically improved human health outcomes since their introduction in the 20th century. Unfortunately, bacteria are now developing resistance to antibiotics at an alarming rate, with many new strains of "superbugs" showing simultaneous resistance to multiple classes of antibiotics. To mitigate the global burden of antimicrobial resistance, we must develop new antibiotics that are broadly effective, safe, and highly stable to enable global access. In this manuscript, we report the development of polyacrylamide-based copolymers as a class of broad-spectrum antibiotics with efficacy against several critical pathogens. We demonstrate that these copolymer drugs are selective for bacteria over mammalian cells, indicating a favorable safety profile. We show that they kill bacteria through a membrane disruption mechanism, which allows them to overcome traditional mechanisms of antimicrobial resistance. Finally, we demonstrate their ability to rehabilitate an existing small-molecule antibiotic that is highly subject to resistance development by improving its potency and eliminating the development of resistance in a combination treatment. This work represents a significant step toward combating antimicrobial resistance.


  • Open Access

    Glassy Surfactants Enable Ultra-High Concentration Biologic Therapeutics

    by Carolyn K. Jons, Alexander N. Prossnitz, Noah Eckman, Changxin Dong, Ashley Utz, Eric A. Appel

    Protein therapeutics, like peptides and antibodies, have become critical to healthcare. Despite their exceptional potency and specificity, biopharmaceuticals are prone to aggregation, often necessitating low formulation concentrations as well as cold storage and distribution to maintain stability. Yet, high doses are required to treat many diseases. To achieve these doses, most approved protein drug products are administered intravenously, imposing excessive burdens on patients and the healthcare system. New approaches are needed to formulate proteins at high concentrations to enable less burdensome subcutaneous injection, preferably in an autoinjector format. To address this challenge, we report a subcutaneously injectable biotherapeutic delivery platform composed of spray-dried protein microparticles suspended in a non-solvent liquid carrier. These microparticles contain only active biopharmaceutical agent and a high glass transition temperature polyacrylamide-derived copolymer excipient affording several key benefits over traditional excipients, including: (i) improved stabilization of biopharmaceuticals through the spray drying process, and (ii) improved morphology and properties of the spray-dried particles, enhancing suspension injectability. Experiments with albumin and human IgG demonstrate that this technology enables ultra-high-concentration protein formulations (exceeding 500 mg/mL) that are injectable through standard needles with clinically relevant injection forces. Additionally, experiments in mice show these ultra-high-concentration formulations reduce required injection volumes without altering pharmacokinetics. This approach could double the number of commercial protein drugs amenable to subcutaneous administration, dramatically reducing burden and improving access to these critical biopharmaceuticals. One Sentence Summary Here we leverage a unique copolymer excipient to enable ultra-high concentration protein formulations with improved stability and amenable to subcutaneous injection that can reduce patient burden, lower costs, and improve access to critical drugs.


  • Open Access

    Defining Structure-Function Relationships of Amphiphilic Excipients Enables Rational Design of Ultra-Stable Biopharmaceuticals

    by Alexander N. Prossnitz, Leslee T. Nguyen, Noah Eckman, Suraj Borkar, Samantha Tetef, Anton A. A. Auzten, Gerald G. Fuller, Eric A. Appel

    Summary: Biopharmaceuticals are the fastest growing class of drugs in the healthcare industry, but their global reach is severely limited by their propensity for rapid aggregation. Currently, surfactant excipients such as polysorbates and poloxamers are used to prevent protein aggregation, which significantly extends shelf-life. Unfortunately, these excipients are themselves unstable, oxidizing rapidly into 100s of distinct compounds, some of which cause severe adverse events in patients. Here, we leverage the highly stable, well-defined, and modular nature of amphiphilic polyacrylamide-derived excipients to isolate the key mechanisms responsible for excipient-mediated protein stabilization. With a library of compositionally identical but structurally distinct amphiphilic copolymers, we quantify multiple relationships between polymer properties and fundamental phenomena to rationally design new ultra-stable surfactant excipients, increasing the stability of a notoriously unstable biopharmaceutical, monomeric insulin, by an order of magnitude. This comprehensive and generalizable understanding of excipient structure-function relationships represents a paradigm shift for the formulation of biopharmaceuticals, moving away from trial-and-error screening approaches towards rational design. TOC Graphic:


  • Open Access

    Sustained Delivery of GLP-1 Receptor Agonists from Injectable Biomimetic Hydrogels Improves Treatment of Diabetes

    by Andrea I. D’aquino, Caitlin L. Maikawa, Leslee T. Nguyen, Katie Lu, Ian A. Hall, Carolyn K. Jons, Catherine M. Kasse, Jerry Yan, Alexander N. Prossnitz, Enmian Chang, et al.

    Glucagon-like peptide-1 (GLP-1) is an incretin hormone and neurotransmitter secreted from intestinal L-cells in response to nutrients to stimulate insulin and block glucagon secretion in a glucose-dependent manner. GLP-1 in itself is rapidly degraded, but long-acting GLP-1 receptor agonists (GLP-1 RAs) have become central in the treatment of T2D because of the beneficial effects extending also beyond glucose control. Currently, these therapeutics must be injected either daily or weekly or taken daily orally, leaving room for technological innovations that enable less frequent administrations, which will reduce patient burden and increase patient compliance. An ideal GLP-1 RA drug product would provide continuous therapy for upwards of four months from a single administration to match the cadence with which T2D patients typically visit their physician. In this work, we leveraged an injectable hydrogel depot technology to develop a long-acting GLP-1 RA drug product. By modulating the hydrogel properties to tune GLP-1 RA retention within the hydrogel depot, we engineered formulations capable of months-long GLP-1 RA delivery. Using a rat model of T2D, we confirmed that a single injection of hydrogel-based therapies exhibits sustained exposure of GLP-1 RA over 42 days, corresponding to a once-every four month therapy in humans. Moreover, these hydrogel therapies maintained optimal management of blood glucose and weight comparable to daily injections of a leading GLP-1 RA drug molecule. The pharmacokinetics and pharmacodynamics of these hydrogel-based long-acting GLP-1 RA treatments are promising for development of novel therapies reducing treatment burden for more effective management of T2D. One Sentence Summary An injectable hydrogel depot technology prolongs delivery of GLP-1 mimics to generate a months-long-acting drug product, enhancing disease management.


  • Open Access

    Microwave-assisted reversible addition–fragmentation chain transfer polymerization of cationic monomers in mixed aqueous solvents

    by Jonathan Tran, Alexander Prossnitz, William Sherwin, Sydney Mikulec, Amanda Ennis, Alisson Magsumbol, Alexandra Jameson, Joan Schellinger, Oscar Calzada

  • Optimizing the Polymer Chemistry and Synthesis Method of PolySTAT, an Injectable Hemostat

    by Robert J. Lamm, Trey J. Pichon, Frederick Huyan, Xu Wang, Alexander N. Prossnitz, Karl T. Manner, Nathan J. White, Suzie H. Pun

    There is a lack of prehospital hemostatic agents, especially for noncompressible hemorrhage. We previously reported PolySTAT, a unimeric, injectable hemostatic agent, that physically cross-links fibrin to strengthen clots. In this work, we sought to improve the water-solubility and synthesis yield of PolySTAT to increase the likelihood of clinical translation, reduce cost, and facilitate future mass production. First, we focused on side-chain engineering of the carrier polymer backbone to improve water-solubility. We found that substitution of the 2-hydroxyethyl methacrylate (HEMA) monomer with glycerol monomethacrylate (GmMA) significantly improved the water-solubility of PolySTAT without compromising efficacy. Both materials increased clot firmness and decreased lysis as measured by rotational thromboelastometry (ROTEM). Additionally, we confirmed the in vivo activity of GmMA-based PolySTAT by improving rat survival in a femoral artery bleed model. Second, to reduce waste, we evaluated PolySTAT synthesis via direct polymerization of peptide monomers. Methacrylamide and methacrylate peptide-monomers were synthesized and polymerized via reversible addition-fragmentation chain transfer (RAFT) polymerization. This approach markedly improved the yield of PolySTAT synthesis while maintaining its biological activity in ROTEM. This work demonstrates the flexibility of PolySTAT to a variety of comonomers and synthetic routes and establishes direct RAFT polymerization of peptide monomers as a potential route of mass production.